STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [144] Tarsus Pharmaceuticals, Inc. SEC Filing

Tarsus ex-officer plans $5.7M share sale

Tarsus Pharmaceuticals, Inc. (TARS) is the issuer for a Form 144 filed for the account of former officer Aziz A. Mottiwala.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) is the issuer for a Form 144 filed for the account of former officer Aziz A. Mottiwala. The notice covers a proposed sale of up to 77,698 shares of common stock, planned in connection with a stock option exercise dated September 1, 2026. The securities are to be sold through Fidelity Brokerage Services LLC, with trading on NASDAQ. The filing also lists prior sales of common stock by Aziz A. Mottiwala during the past three months.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 77,698 shares Common stock proposed for sale in connection with a stock option exercise dated 09/01/2026
Approximate aggregate market value of proposed sale 5,746,846.04 Aggregate market value for 77,698 shares of common stock listed in the securities information section
Shares sold on 08/19/2026 53,043 shares Common stock sold by Aziz A. Mottiwala on 08/19/2026
Aggregate value on 08/19/2026 sale 3,842,690.85 Aggregate value of common stock sold on 08/19/2026
Shares sold on 08/25/2026 81,332 shares Common stock sold by Aziz A. Mottiwala on 08/25/2026
Aggregate value on 08/25/2026 sale 5,843,886.22 Aggregate value of common stock sold on 08/25/2026
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common | 09/01/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"as attorney-in-fact for Aziz Mottiwala"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for TARS disclose about Aziz A. Mottiwala?
The Form 144 identifies Aziz A. Mottiwala, a former officer of Tarsus Pharmaceuticals, Inc. (TARS), as the person for whose account the securities may be sold, with sales reported and proposed under Rule 144.

How many TARS shares are proposed to be sold in this Form 144?
The notice covers a proposed sale of up to 77,698 shares of Tarsus Pharmaceuticals, Inc. common stock, with the transaction tied to a stock option exercise dated September 1, 2026.

What prior sales of TARS stock by Aziz A. Mottiwala are reported?
The filing reports two prior sales of Tarsus common stock: 53,043 shares sold on 08/19/2026 for an aggregate of 3,842,690.85, and 81,332 shares sold on 08/25/2026 for an aggregate of 5,843,886.22.

What is the approximate market value of the TARS shares proposed to be sold?
The proposed sale of 77,698 shares of Tarsus common stock has an approximate aggregate market value of 5,746,846.04, as stated in the Form 144 securities information section.

Which broker is handling the proposed TARS share sale in this Form 144?
The proposed sale of Tarsus Pharmaceuticals, Inc. common stock is listed under Fidelity Brokerage Services LLC, with the securities to be traded on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR